Advisory Committee to the Director, Centers for Disease Control and Prevention, 18139-18140 [2023-06258]

Download as PDF Federal Register / Vol. 88, No. 58 / Monday, March 27, 2023 / Notices includes the Frank L. Farrar Dynasty Trust II, the Frank L. Farrar and Patricia J. Farrar 2022 Irrevocable Trust, Robert Farrar as trustee of the trusts and individually, all of Britton, South Dakota; Jeanne Farrar Orfield and Samuel Farrar Orfield, Minneapolis, Minnesota; and Anne M. Farrar, St. Paul, Minnesota. Board of Governors of the Federal Reserve System. Michele Taylor Fennell, Deputy Associate Secretary of the Board. [FR Doc. 2023–06284 Filed 3–24–23; 8:45 am] BILLING CODE 6210–01–P FEDERAL RESERVE SYSTEM ddrumheller on DSK120RN23PROD with NOTICES1 19:19 Mar 24, 2023 Jkt 259001 useful and necessary to improve the delivery of government services. Board of Governors of the Federal Reserve System. Michele Taylor Fennell, Deputy Associate Secretary of the Board. [Docket No. CDC–2023–0019] Beth Anne Killoran, Deputy Chief Information Officer. [FR Doc. 2023–06174 Filed 3–24–23; 8:45 am] BILLING CODE 6820–AB–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee to the Director, Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting and request for comment. AGENCY: BILLING CODE P The notificants listed below have applied under the Change in Bank Control Act (‘‘Act’’) (12 U.S.C. 1817(j)) and of the Board’s Regulation LL (12 CFR 238.31) to acquire shares of a savings and loan holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551–0001, not later than April 11, 2023. A. Federal Reserve Bank of Minneapolis (Stephanie Weber, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291. Comments can also be sent electronically to MA@mpls.frb.org: 1. Sally A. Farrar, Arkansaw, Wisconsin; Arthur Turner, Lauderdale, Minnesota; Reid Turner, Iowa City, Iowa; and Mary S. Farrar Turner and Frank Turner, both of Pierre, South Dakota; to retain voting shares of VerDate Sep<11>2014 Beresford Bancorporation, Inc., Britton, South Dakota, and thereby indirectly retain voting shares of First Savings Bank, Beresford, South Dakota, as part of a group acting in concert that includes the Frank L. Farrar Dynasty Trust II, the Frank L. Farrar and Patricia J. Farrar 2022 Irrevocable Trust, Robert Farrar as trustee of the trusts and individually, all of Britton, South Dakota; Jeanne Farrar Orfield and Samuel Farrar Orfield, Minneapolis, Minnesota; and Anne M. Farrar, St. Paul, Minnesota. [FR Doc. 2023–06283 Filed 3–24–23; 8:45 am] Change in Bank Control Notices; Acquisitions of Shares of a Savings and Loan Holding Company 18139 GENERAL SERVICES ADMINISTRATION In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee to the Director, Centers for Disease Control and Prevention (ACD, CDC). This is a hybrid meeting, accessible both in person and virtually (webcast live via the World Wide Web). It is open to the public and limited only by the space available. Time will be available for public comment. SUMMARY: [OMB Control No. 3090–XXXX; Docket No. 2022–0001; Sequence No. 16] Submission for OMB Review; GSA Equity Study on Remote Identity Proofing; Correction Technology Transformation Services (TTS), General Services Administration (GSA). ACTION: Notice; correction. AGENCY: The General Services Administration published a document in the Federal Register of February 10, 2023, concerning a request for comments regarding a new information collection. The document contained information in the discussion and analysis section that is no longer needed. SUMMARY: FOR FURTHER INFORMATION CONTACT: Tiffany Andrews or Gerardo E. CruzOrtiz by phone 202–969–0772 or via email to identityequitystudy@gsa.gov. SUPPLEMENTARY INFORMATION: Correction In the Federal Register of February 10, 2023, in FR Doc. 2023–03131, on page 8864, in the second column, correct the sixth paragraph to read: GSA is consulting with the Center for Information Technology Research (CITeR) and researchers at Clarkson University to ensure that the statistical design of the study is sound. GSA representatives have met with staff from other government agencies that have conducted similar research. These groups have agreed that the collection is PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 The meeting will be held on May 11, 2023, from 9 a.m. to 3 p.m., EDT (times subject to change). Written comments must be received on or before May 1, 2023. ADDRESSES: Meeting address: CDC Roybal Campus, Building 19, Room 247 and 248, 1600 Clifton Road NE, Atlanta, Georgia 30329–4027. The conference rooms combine to accommodate approximately 60 people. Please note that the meeting location, the CDC Roybal Campus, is a federal facility and in-person access is limited to United States citizens unless prior authorizations, taking up to 30 to 60 days, have been made. Visitors must follow all directions for access to CDC facilities. Directions for visitors to CDC, including safety requirements related to COVID–19, are available at https:// www.cdc.gov/screening/visitors.html. Registration: You must register to attend this meeting in person. If you wish to attend in person, please submit a request by email to ACDirector@ cdc.gov or by telephone at (404) 718– 5028 at least 5 business days in advance DATES: E:\FR\FM\27MRN1.SGM 27MRN1 ddrumheller on DSK120RN23PROD with NOTICES1 18140 Federal Register / Vol. 88, No. 58 / Monday, March 27, 2023 / Notices of the meeting. No registration is required to view the meeting via the World Wide Web. Information for accessing the webcast will be available at https://www.cdc.gov/about/advisorycommittee-director/. Written comments: You may submit comments, identified by Docket No. CDC–2023–0019, by either of the methods listed below. Do not submit comments for the docket by email. CDC does not accept comments for the docket by email. • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Bridget Richards, MPH, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21–10, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2023–0019. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https:// www.regulations.gov. Written comments received in advance of the meeting will be included in the official record of the meeting. FOR FURTHER INFORMATION CONTACT: Bridget Richards, MPH, Office of the Chief of Staff, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21–10, Atlanta, Georgia 30329–4027; Telephone: (404) 718–5028; Email: ACDirector@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee to the Director, CDC, shall (1) make recommendations to the Director regarding ways to prioritize the activities of the agency in alignment with the CDC Strategic Plan required under section 305(c); H.R. 2617–1252; (2) advise on ways to achieve or improve performance metrics in relation to the CDC Strategic Plan, and other relevant metrics, as appropriate; (3) provide advice and recommendations on the development of the Strategic Plan, and any subsequent updates, as appropriate; (4) advise on grant, cooperative agreements, contracts, or other transactions, as applicable; (5) provide other advice to the Director, as requested, to fulfill duties under sections 301 and 311; and (6) appoint subcommittees. The Committee recommends ways to prioritize CDC’s activities, improve results, and address health disparities. It also provides guidance to help CDC work more VerDate Sep<11>2014 19:19 Mar 24, 2023 Jkt 259001 effectively with its various private and public sector constituents to make health protection a practical reality. Matters To Be Considered: The agenda will include discussions regarding CDC’s current and future work in the following topic areas: (1) communications; (2) laboratory quality; (3) global health; (4) health equity; (5) response readiness; and (6) data and surveillance. The ACD will hear reports from its workgroups on data and surveillance, laboratory quality, and health equity topics. In addition, the ACD will hear an update on communications, global health, and response readiness. Agenda items are subject to change as priorities dictate. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on March 27, 2023 through April 28, 2023. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting In accordance with 5 U.S.C. 1009(d), the Centers for Disease Control and Prevention (CDC) announces the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. Name of Committee: Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH). Dates: June 6–7, 2023. Times: 11 a.m.–5 p.m., EDT. Place: Teleconference. Agenda: The meeting will convene to address matters related to the conduct of Study Section business and for the Study Section to consider safety and occupational health-related grant applications. For Further Information Contact: Michael Goldcamp, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia 26506. Telephone: (304) 285–5951; Email: MGoldcamp@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2023–06256 Filed 3–24–23; 8:45 am] BILLING CODE 4163–18–P [FR Doc. 2023–06258 Filed 3–24–23; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00031 Fmt 4703 Sfmt 9990 E:\FR\FM\27MRN1.SGM 27MRN1

Agencies

[Federal Register Volume 88, Number 58 (Monday, March 27, 2023)]
[Notices]
[Pages 18139-18140]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06258]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2023-0019]


Advisory Committee to the Director, Centers for Disease Control 
and Prevention

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee to the Director, Centers for Disease Control and 
Prevention (ACD, CDC). This is a hybrid meeting, accessible both in 
person and virtually (webcast live via the World Wide Web). It is open 
to the public and limited only by the space available. Time will be 
available for public comment.

DATES: The meeting will be held on May 11, 2023, from 9 a.m. to 3 p.m., 
EDT (times subject to change).
    Written comments must be received on or before May 1, 2023.

ADDRESSES: 
    Meeting address: CDC Roybal Campus, Building 19, Room 247 and 248, 
1600 Clifton Road NE, Atlanta, Georgia 30329-4027. The conference rooms 
combine to accommodate approximately 60 people.
    Please note that the meeting location, the CDC Roybal Campus, is a 
federal facility and in-person access is limited to United States 
citizens unless prior authorizations, taking up to 30 to 60 days, have 
been made. Visitors must follow all directions for access to CDC 
facilities. Directions for visitors to CDC, including safety 
requirements related to COVID-19, are available at https://www.cdc.gov/screening/visitors.html.
    Registration: You must register to attend this meeting in person. 
If you wish to attend in person, please submit a request by email to 
[email protected] or by telephone at (404) 718-5028 at least 5 
business days in advance

[[Page 18140]]

of the meeting. No registration is required to view the meeting via the 
World Wide Web. Information for accessing the webcast will be available 
at https://www.cdc.gov/about/advisory-committee-director/.
    Written comments: You may submit comments, identified by Docket No. 
CDC-2023-0019, by either of the methods listed below. Do not submit 
comments for the docket by email. CDC does not accept comments for the 
docket by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Bridget Richards, MPH, Centers for Disease Control 
and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 
30329-4027. Attn: Docket No. CDC-2023-0019.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov. 
Written comments received in advance of the meeting will be included in 
the official record of the meeting.

FOR FURTHER INFORMATION CONTACT: Bridget Richards, MPH, Office of the 
Chief of Staff, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027; 
Telephone: (404) 718-5028; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee to the Director, CDC, shall (1) 
make recommendations to the Director regarding ways to prioritize the 
activities of the agency in alignment with the CDC Strategic Plan 
required under section 305(c); H.R. 2617-1252; (2) advise on ways to 
achieve or improve performance metrics in relation to the CDC Strategic 
Plan, and other relevant metrics, as appropriate; (3) provide advice 
and recommendations on the development of the Strategic Plan, and any 
subsequent updates, as appropriate; (4) advise on grant, cooperative 
agreements, contracts, or other transactions, as applicable; (5) 
provide other advice to the Director, as requested, to fulfill duties 
under sections 301 and 311; and (6) appoint subcommittees. The 
Committee recommends ways to prioritize CDC's activities, improve 
results, and address health disparities. It also provides guidance to 
help CDC work more effectively with its various private and public 
sector constituents to make health protection a practical reality.
    Matters To Be Considered: The agenda will include discussions 
regarding CDC's current and future work in the following topic areas: 
(1) communications; (2) laboratory quality; (3) global health; (4) 
health equity; (5) response readiness; and (6) data and surveillance. 
The ACD will hear reports from its workgroups on data and surveillance, 
laboratory quality, and health equity topics. In addition, the ACD will 
hear an update on communications, global health, and response 
readiness. Agenda items are subject to change as priorities dictate.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on March 27, 2023 through April 28, 2023.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-06258 Filed 3-24-23; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.